We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
12 January 2017
Anokion located in Lausanne and Celgene Corp. (NASDAQ:CELG) partnered to use Anokion's biotech immune tolerizing platform to develop therapies for autoimmune diseases. Anokion received a $45 m upfront payment and is eligible to receive a future payment of an additional $10 m based on certain preclinical development achievements. As part of the strategic collaboration agreement, Celgene obtained an equity interest in Anokion and the exclusive right to acquire Anokion at pre-specified option exercise points. Anokion’s most advanced approach to immune tolerance harnesses the body’s natural tolerance mechanism of apoptotic or aging cells. It involves engineering antigens, relevant to a broad range of autoimmune disorders, to bind glycophorin A, a surface protein unique to erythrocytes or red blood cells.
VISCHER (together with Skadden, Arps, Slate, Meagher & Flom LLP) have been advising Anokion in this transaction. The team at VISCHER was led by Dr. Matthias Staehelin (Partner, Corporate) and Nadia Tarolli (Partner, Tax) with Vincent Reardon and Luzius Zumstein (both Associates, Corporate).
Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law, Swiss Certified Tax Expert (2008)
Attorney at Law
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...